Lupus & antiphospholipid syndrome
Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: A case series of 18 patients
Authors' conclusion
Anifrolumab is highly effective in various skin manifestations of SLE, even after prior failure to multiple treatments.
Study context
- Population
- Patients with refractory cutaneous systemic lupus erythematosus (SLE), three Rheumatology Departments in Greecerefractory to mean 6.3 agents
- Participants
- 18 patients
- Outcome
- Improvement in SLEDAI-2K, physician global assessment (PGA) and CLASI; clinically relevant skin improvement defined as CLASI decrease ≥50% (CLASI50) from baseline
Methodological detailsmulticentre (three Rheumatology Departments)
- Multicentre (three Rheumatology Departments)
Main finding
As reported in the abstract
CLASI50 (decrease ≥50% in CLASI from baseline) · after a mean 8.5 (4.6) months
CLASI50 achieved in highly refractory patients
16 of 18
89%
Observational data: associations, not effects.
Further findings
Significant improvement in general lupus and cutaneous disease activity, and GC tapering · after a mean 8.5 (4.6) months
- Patients with significant improvement
- 89% (n = 16/18)
SLEDAI, mean (SD) · last visit
- Mean SLEDAI at anifrolumab (ANI) initiation
- 7.4 (2.7)
- Mean SLEDAI at last visit
- 3.4 (1.9)
CLASI (Activity/Damage), mean (SD) · last visit
- Mean CLASI (Activity/Damage) at baseline
- 13.9 (9.7)/2.9 (4.6)
- Mean CLASI (Activity/Damage) at last visit
- 2.1 (2.4)/1.4 (2.2)
Daily prednisone dose, mean (SD) · last visit
- Mean prednisone dose at ANI initiation (mg/day)
- 4.9 (4.5)
- Mean daily prednisone dose at last visit
- 2.4 (2.2)
DORIS remission
- Patients attaining DORIS remission
- two (11.1%)
LLDAS
- Patients attaining LLDAS
- eleven (61.1%)
Safety
| Outcome | Values |
|---|---|
| Discontinuation due to varicella-zoster virus infection · after 4 infusions | ANI 1 events |
| Skin flare after temporary discontinuation due to Covid 19 infection | ANI 1 events |
Original publication
Anifrolumab for systemic lupus erythematosus with multi-refractory skin disease: A case series of 18 patients. Lupus. Published 4 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →